ArticlePulmonary circulation2026
Long-Term Outcome of Pulmonary Artery Hypertension-Specific Therapy in Patients With Portopulmonary Hypertension: A Multi-Institutional Database Case Series Study.
Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portopulmonary hypertension (PoPH) is a subtype of pulmonary arterial hypertension (PAH) associated with portal hypertension, occurring in 2%-6% of cirrhotic patients. Although guidelines recommend routine echocardiography before transplantation, the prevalence, and outcomes of PAH-specific therapy in cirrhotic patients remain unclear. We retrospectively analyzed 4,113 cirrhotic patients who underwent transthoracic echocardiography (TTE) between 2008 and 2019 using the Chang Gung Research Database. Patient characteristics, medication, echocardiographic findings, right heart catheterization (RHC) results and clinical outcome were collected from medical records and retrospectively analyzed by the investigators. Among 3243 patients with completed TTE, 709 (21.9%) had elevated tricuspid regurgitation peak gradient (TRPG ≥ 35 mmHg), suggesting pulmonary hypertension. There were 52 patients underwent RHC at our center, of whom 46 (88.5%) fulfilled hemodynamic criteria for PoPH. Additionally, seven patients with externally confirmed PoPH were included, yielding 53 patients in the final analysis. Among them, 13 patients received PAH-specific therapy with significant TRPG reduction but shorter mean survival (median survival 22.6 vs 78.9 months,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.